Toleranzia’s tolerogens are highly flexible – the disease-specific proteins may be adapted to a variety of autoimmune diseases.

Apart from Toleranzia’s primary indication, myasthenia gravis, Toleranzia has evaluated its technology portfolio in three other indications – positive treatment effects have been achieved in relevant animal models of diabetes type 1, rheumatoid arthritis, and multiple sclerosis. This validates Toleranzia’s technology as a technology portfolio with broad application potential for the development of new therapies in autoimmune diseases.

Below is a table of the indications that Toleranzia works in.

Autoimmune disease Positive treatment results
in animal models
Development stage
Main focus
Myasthenia gravis (MG) Yes Preclinical phase
Other indications
Rheumatoid arthritis (RA) Yes Discovery phase
Multipele sclerosis (MS) Yes Discovery phase
Diabetes type 1 (T1D) Yes Discovery phase